ReviewPsoriasis (Auckland, N.Z.)2025

Bimekizumab: The First FDA-Approved Dual IL-17A/IL-17F Inhibitor for Plaque Psoriasis - A Comprehensive Literature Review.

Sukainah Ahmed Al Alshaikh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.